A Cheaper Dose of Mounjaro Draws South Korean Patients to Japan

A regulatory change implemented on Thursday now allows travelers to legally bring personal prescription medicines—including up to a three-month supply—into South Korea. This policy shift has triggered immense interest among South Koreans seeking Mounjaro, a popular weight-loss drug developed by Eli Lilly that is sold in Japan at prices substantially lower than those domestically. Internet users have affectionately nicknamed the trend "Sushijaro," combining sushi and the drug's brand name as medical tourism to Japan surges.
Japanese clinics are actively catering to this influx by advertising Korean-language consultations, hotel deliveries, and discounted prescriptions. While monthly prices in Japan start around 7,000 yen for a 2.5-milligram dose, calculations show that patients can save hundreds of thousands of won even after factoring in round-trip airfare and hotel accommodations compared to domestic telemedicine prices.
Despite the clear financial incentives for consumers, pharmaceutical industry officials have expressed serious concerns regarding the trend. They warn that easier access across borders could encourage inappropriate use without thorough medical evaluations, and caution that transporting temperature-sensitive medication internationally without proper storage could compromise its safety and effectiveness.
Furthermore, language barriers and difficulties maintaining follow-up communication with overseas physicians present potential health risks for patients. Industry experts predict that these cross-border prescription trips will continue to thrive unless domestic prices for Mounjaro see a significant decrease, leaving regulators with the challenge of balancing patient access with necessary medical safeguards.
Edited using generative AI tools.
Source: http://koreabizwire.com/a-cheaper-dose-of-mounjaro-draws-south-korean-patients-to-japan/363236 |